Patients & Caregivers
GI Problems Common in Neurofibromatosis Type 1
NF-1 patients often suffer from chronic constipation that can greatly impact their health and quality of life.
Two Potential Hepatocellular Carcinoma Treatments Get Orphan Drug Designations
Singapore-based clinical-stage biotechnology company Lion TCR was granted 2 orphan drug designations today by the U.S. Food and Drug Administration (FDA) for T-cell therapies.
Data Not Promising for CA4P to Treat Ovarian Cancer
Interim analysis of a Phase 2/3 study testing CA4P in platinum-resistant ovarian cancer patients is struggling to meet its primary endpoint.
Clinical Hold Lifted for Head and Neck Cancer Study
Head and neck cancers begin in the mouth, nose, throat, larynx, sinuses, or salivary glands. Most are squamous cell carcinomas.
Acute Myelogenous Leukemia Treatment Gets Orphan Drug Designation
H3B-8800, was granted orphan drug designation by the FDA for the treatment of patients with acute myeloid leukemia, and chronic myelomonocytic leukemia.
Twin Saves Sister from Rare Cancer with Radical Procedure
Mariann's plexiform fibrohistiocytic sarcoma had taken over most of her back. Her treatment required a donor that was compatible.
Screening for Nasopharyngeal Cancer Using Epstein-Barr virus DNA
Nasopharyngeal cancer has been linked to the Epstein-Barr virus.
Kadmon Granted FDA Orphan Drug Designation for Rare Lung Cancer Treatment
The FDA granted orphan drug designation to tesevatinib for treatment of non-small cell lung cancer with epithelial growth factor receptor-activating mutations.
Erdheim-Chester Disease Treatment Gets FDA Priority Review and Breakthrough Therapy Designation
The FDA accepted a supplemental New Drug Application and granted Priority Review for Zelboraf, a therapy for Erdheim-Chester disease with a BRAF V600 mutation.
FDA Approves First Treatment for Chronic Graft Versus Host Disease
TheFDA has approved Imbruvica (ibrutinib) for treating adults with chronic graft versus host disease (cGVHD) after failure of one or more treatments.
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.